Cover Image
市場調查報告書

細胞株開發服務的全球市場

Cell Line Development Services Market, 2017-2027

出版商 ROOTS ANALYSIS 商品編碼 534099
出版日期 內容資訊 英文 278 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
細胞株開發服務的全球市場 Cell Line Development Services Market, 2017-2027
出版日期: 2017年07月26日 內容資訊: 英文 278 Pages
簡介

本報告提供細胞株開發服務的市場相關分析,服務概要和市場結構,企業間競爭結構、現狀,市場趨勢預測 (今後11年份),主要企業簡介,各地區、細胞株的各原料、各等級詳細趨勢,主要企業 (供應商)的簡介、業績,今後的市場機會等調查、考察。

第1章 序章

第2章 摘要整理

第3章 簡介

第4章 市場概要

  • 概要
  • 細胞株開發服務行業者:市場環境

第5章 競爭環境

  • 概要
  • 各地區分析
  • 熱圖分析
  • 細胞株的各原料、各企業規模分析

第6章 主要企業簡介

第7章 其他的企業簡介

第8章 細胞株的儲存庫業者

第9章 市場預測

  • 概要
  • 預測手法
  • 市場資料主要的前提條件
  • 整體市場趨勢 (今後11年份)
  • 今後的市場機會:細胞株的各原料 (今後11年份)
    • 哺乳類細胞
    • 細菌細胞
    • 昆蟲細胞
    • 其他
  • 今後的市場機會:各地區 (今後11年份)
    • 北美各國
    • EU各國
    • 亞洲各國
    • 其他
  • 今後的市場機會:細胞株的各等級 (今後11年份)
    • GMP (合理製造標準) 依據的細胞株的情況
    • 非GMP依據的細胞株的情況

第10章 分析方法 (調查受訪者、細胞株概要)

第11章 結論

第12章 採訪概要 (共4家)

第13章 附錄1:資料一覽

第14章 附錄2:企業、組織一覽

圖表一覽

分析對象企業 (共323家)

目錄
Product Code: RA10086

The growing pipeline of biological drugs has resulted in a continuous increase in the demand for different types of cell lines. More than 650 biologics have been approved till date, and over 1,500 are under clinical development. Additionally, the loss of patent exclusivity of several biologics in the coming years is likely to be followed by the entry of numerous biosimilars as many companies compete to grab a share of already established drug markets. The importance of cell lines in other areas, such as drug screening, gene functional studies, cell-based assay development, diagnostics and tissue engineering, has resulted in further increase in the demand for different types of cell lines. The rapid progression of biological drug candidates through various phases of development, coupled with the growing demand of cell lines for other applications, presents significant opportunities to cell line development service providers.

The market already has a wide array of well-established players, mid-sized companies and start-ups. Several industry players are contributing to the production of GMP and non-GMP grade cell lines that are obtained from mammalian, microbial, insect-derived, avian, marine, reptilian and other sources. Stakeholders have entered into multiple partnerships / collaborations in order to improve and scale-up production processes, and expand their capabilities. Considering the heightened activity in this domain, we believe the market is likely to evolve at a steady pace in the mid to long term, driven primarily by the increasing demand for cell lines, and advances in technology platforms and production methodologies.

Synopsis:

The ‘Cell Line Development Services Market, 2017 - 2027 ’ report provides an extensive study of the rapidly growing market of cell lines. Cells obtained from mammalian and microbial sources are widely used for the development and manufacturing of biotherapeutic products, such as recombinant proteins, antibodies and vaccines. Mammalian cell lines, owing to their inherent high productivity and ability to produce complex biopharmaceuticals, are relatively more preferred. At the same time, microbial cell lines are also widely used due to their less complex nature, low cost and high versatility.

As mentioned earlier, in addition to the large number of biologics that are already available in market, many are under various stages of development. In fact, close to 50% of product candidates in the current development pipeline are in the preclinical stage. Moreover, a number of important biologics, such as Aransep®, Avastin®, Herceptin®, HUMIRA®, Neulasta® and REMICADE®, are approaching patent expiration, and several companies are already engaged in the development of biosimilars and biobetters. As of May 2017, five biosimilars in the US and 28 in Europe have been approved. In addition to the US and EU, several companies based in Asia are also focused on the development of biosimilars. These developments have led to an upward surge in the demand for highly-productive and stable cell lines. High yielding cell lines, capable of producing top quality biopharmaceuticals, help in significantly reducing development and manufacturing costs. Hence, several companies have designed and developed innovative systems / technologies / proprietary manufacturing processes in order to optimize manufacturing costs and production timelines of the overall cell line development process. In addition to development-related services, several cell line manufacturers provide other services related to cell lines as a part of their respective services portfolios; examples of these services include cell line characterization, cell banking, cell bank characterization, process development and commercialization of reagents / equipment. It is also important to highlight that some of these companies offer cGMP production of biologics and fill / finish of end products as well.

This study presents an in-depth analysis of companies that are actively involved in providing cell line development services. In addition to other elements, the study features:

  • A discussion on the database of cell line development service providers along with information on the location of their manufacturing facilities, distribution of cell lines based on the source from which they are obtained (mammalian, microbial, insect-derived, avian, marine and reptilian), type of cell lines (recombinant, hybridoma and primary cell lines), technology used for the production of cell lines, purpose of production (R&D, diagnostics, biomanufacturing and tissue engineering), and other associated services (cell line characterization, cell banking, cell bank characterization, process development, cGMP manufacturing of biologics, fill / finish of end products and commercialization of reagents / equipment).
  • A detailed analysis of the database presented as three schematic representations; a world map depicting the most active geographies in terms of the presence of cell line development facilities, a heat map representing the distribution of database companies on the basis of their location (continent-wise distribution), year of establishment and cell line development capabilities, and a logo landscape signifying the distribution of companies based on the number of employees and the source from which cell lines are obtained.
  • Elaborate profiles of key industry players that have proprietary technologies for the development of cell lines and offer cell line characterization, cell banking and cGMP production of biologics as part of their services portfolios; each profile features an overview of the company, its financial performance, information on cell line development services and proprietary technology, manufacturing facilities, expansions and collaborations, and a comprehensive future outlook.
  • Profiles of non-industry players (cell line repositories) that play an active role in the development of cell lines and offer affiliated services; each profile features an overview of the repository and a brief description about its cell line development services.
  • Potential future growth opportunities in the cell line development market, segmented by regions, source and grade of cell lines. For the purposes of this analysis, we took into consideration several parameters, such as the number of companies involved, price of cell lines depending upon whether they are characterized or uncharacterized, source of cell lines, and average annual cell line development projects undertaken by companies.

We have provided informed estimates of the size of the market in the short to mid-term and long term for the period 2017-2027. To account for the uncertainties associated with the development of cell lines and to add robustness to our model, we have provided three forecast scenarios portraying conservative, base and optimistic tracks of the market's evolution. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 100 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. The insights presented in this study were also influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Fan Chen (Vice President Bioprocessing, LakePharma), Michael Pointek(Managing Director, Artes Biotechnology), Nienke Smits (Business Development, Modiquest) and Oscar Hoogteijling (Business Development Manager, Bioceros).

Example Highlights:

  • 1. Over 180 companies are actively providing cell line development services to several biopharmaceutical companies. Majority of these companies are located in North America (45%) and the EU (35%).
  • 2. Currently, more than 60% of cell line development service providers focus on the development and generation of mammalian cell lines, which are the most popular due to their ability to produce highly complex recombinant proteins, antibodies and vaccines that cannot be produced in other types of cell lines. Microbial cell lines are the second most important type; approximately 15% of the companies that we identified claim to provide microbial cell line development services.
  • 3. Cell lines are used for several purposes such as R&D studies, biomanufacturing, diagnostics and tissue engineering. Majority of the companies (over 45%) produce cell lines for R&D purposes; this is followed by companies producing cell lines for biomanufacturing purposes (over 40%). R&D activities include the production of cell based assays, reporter cell lines, ion channel expressing cell lines, drug discovery and screening, and production of non-GMP grade antibodies and other proteins. Examples of companies providing cell lines for R&D applications include (in alphabetical order) Abcam, Altogen Labs, Applied Biological Materials, ATGCell, Bhat Bio-Tech, BPS Bioscience, CreaCell, DiscoverX, Eurofins Scientific, Euroscreen, GeneCopoeia GVK Biosciences, InvivoGen, SB Drug Discovery, System Biosciences, Trend Pharma & Tech, Vectalys, WatsonBio Sciences. Similarly, biomanufacturing involves the production of different types of therapeutic products (monoclonal and polyclonal antibodies, recombinant proteins and vaccines) and biosimilars.Examples of companies producing cell lines for biomanufacturing applications include (in alphabetical order) AbbVie, Abzena, Batavia Biosciences, Biovian, Boehringer Ingelheim BioXcellence, CMC Biologics, Cobra Biologics, FUJIFILM Diosynth Biotechnologies, Inno Biologics, LFB Biomanufacturing, MassBiologics and Patheon.
  • 4. More than 20% of the database companies providing cell line development services also offer cell banking (stand-alone service) and approximately 15% provide cell line characterization services (stand-alone service) to their customers. Some other services included as a part of service portfolio are cGMP manufacturing of biologics, fill / finish and services related to reagents / equipments. Examples of companies offering some of the aforementioned services include (in alphabetical order) Celonic, EuBiologics, Fusion Antibodies, Goodwin Biotechnology, Lonza, Nanotherapeutics, ProBioGen, Rentschler Biotechnologie, Selexis and Syngene International.
  • 5. The heightened competition and growing demand for cell lines has resulted in the emergence of several novel and innovative technologies, lowering of manufacturing costs and production timelines. Examples of some companies that have developed proprietary technologies for production of cell lines include (in alphabetical order) Abzena (Composite CHO™ technology), ACROBiosystems (HEKMax® Stable Cell Line Technology), BioFactura (StableFast™ Biomanufacturing Platform), Batavia Biosciences (STEP® technology), Celltheon (SMART™ expression platform), Celonic (CHOvolution™ / SEFEX platform), Cevec Pharmaceuticals (CAP®GO platform) and Selexis (SUREtechnology Platform™).
  • 6. Stakeholders have extensively collaborated during the last few years for a variety of purposes, such as out / in licensing of technologies, development of cell lines for specific drug candidates and acquisition / development of manufacturing facilities. For instance, Progenics Pharmaceuticals (June 2016), Sanofi Biologics (February 2017) and Xencor (November 2016) collaborated with Selexis to gain access to Selexis' CHO-M Cell Line™ technology and the SURE technology Platform. More recently, in February 2017, Lonza and Sanofi entered into a joint venture agreement to establish a large scale mammalian cell culture facility in Visp, Switzerland, for the production of monoclonal antibodies. Earlier, in September 2015, Abzena acquired PacificGMP with an aim to expand its cell line development services. PacificGMP was a provider of contract process development, and non-GMP and cGMP manufacturing services for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene and cell therapy products.
  • 7. We expect the cell line development services market to grow at an annualized rate of ~10% over the course of next decade; this growth will be driven by the robust pipeline of biologics, increasing number of approvals of biological drug candidates, growing adoption of biosimilars, introduction of advanced production technologies, capability and capacity expansions, and the establishment of new cell line generation facilities. As the market evolves, cell lines obtained from mammalian sources will continue to form a major portion of the overall cell line development services market (~80%). North America and EU, with ~40% and ~35% of the current market, respectively, are likely to remain the major manufacturing hubs in the coming decade.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the cell line development services market over the coming decade.

Chapter 3 provides a general introduction to the various types of cell lines. It includes a detailed discussion on the sources, selection and maintenance conditions, key features, applications and limitations of currently available cell lines. The chapter also provides a brief description of cell line characterization and cell banking services.

Chapter 4 identifies the contract service providers that are actively involved in the development of cell lines. The chapter provides details on the cell line development capabilities of these organizations, geographic location of their facilities, information on the proprietary technology (if any) used by the company for cell line development, type of cell lines produced by the company (recombinant, hybridoma and primary) and applications of the cell lines (such as for R&D activities, biomanufacturing, diagnostics and tissue engineering). The chapter also provides the distribution of companies based on the other services that they offer; these include cell line characterization, cell bank characterization, cell banking, process development, cGMP manufacturing of biologics, fill / finish and commercialization of reagents / equipment.

Chapter 5 presents a detailed analysis of the cell line development services market landscape. It features a schematic representation on world map, highlighting the key geographical locations of cell line manufacturing facilities. Further, we have provided a heat map analysis representing the distribution of companies on the basis of their location, year of establishment and cell line development capabilities. The chapter also provides a logo landscape of companies based on their size (employee base) and source of cell lines produced.

Chapter 6 offers detailed profiles of contract cell line development service providers that have developed proprietary technology / technologies for the production of cell lines. Each profile provides an overview of the company, its financial performance, details on its proprietary technology / technologies, information on its cell line manufacturing capabilities, recent investments / expansions, relevant collaborations and partnerships that have been inked over the last few years, and a comprehensive future outlook.

Chapter 7 features profiles of additional players that offer cell line characterization, cell banking and cGMP production services, apart from cell line development services. However, the companies included in this chapter have not developed any proprietary technology / technologies for producing cell lines.

Chapter 8 features profiles of key non-industry players (cell line repositories) that are playing an active role in providing cell line development services. Each profile provides a brief overview of the organization and the services it offers.

Chapter 9 presents a 10-year sales forecast, highlighting the likely growth of the market for cell lines development services. We have segregated the broader opportunity by source of cell lines (mammalian, microbial, insect-derived and others), regions (North America, Europe, Asia and the Rest of the World) and grade of cell lines (GMP and non-GMP). Our predictions are backed by robust analysis of data procured from both secondary and primary sources. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic forecast scenarios.

Chapter 10 presents insights from a survey that we conducted for this study. The participants, who were primarily members of the Senior Management or CXO level representatives, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 11 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and trends that are likely to determine the future evolution of this segment of the industry.

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. In this chapter, we have presented detailed transcripts of discussions held with Fan Chen (VP BioProcessing, LakePharma), Michael Pointek(Managing Director, Artes Biotechnology), Nienke Smits (Business Development, ModiQuest) and Oscar Hoogteijling (Business Development Manager, Bioceros).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 14 is an appendix,which contains the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Introduction

  • 3.1. Chapter Overview
  • 3.2. Introduction to Cell Culture
    • 3.2.1. Primary Cell Culture
    • 3.2.2. Secondary Cell Culture
  • 3.3. Types of Cell Lines
    • 3.3.1. Recombinant Cell Lines
    • 3.3.2. Hybridoma Cell Lines
    • 3.3.3. Finite Cell Lines
    • 3.3.4. Continuous Cell Lines
  • 3.4. Sources of Cell Lines
    • 3.4.1. Mammalian
    • 3.4.2. Non-Mammalian
  • 3.5. Selection of a Cell Line
  • 3.6. Maintenance of Cell Lines
  • 3.7. Key Features of a Cell Lines
  • 3.8. Applications of Cell Lines
  • 3.9. Key Concerns Associated with Cell Lines
  • 3.10. Cell Line Characterization
  • 3.11. Cell Banking
  • 3.12. Need for Outsourcing Cell Line Related Operations

4. Market Overview

  • 4.1. Chapter Overview
  • 4.2. Cell Line Development Services Providers: Market Landscape
    • 4.2.1. Distribution by Location of Manufacturing Facility
    • 4.2.2. Distribution by Source of Cell Lines
    • 4.2.3. Distribution by Type and Applications of Cell Lines
    • 4.2.4. Distribution by Other Services Related to Cell Line Development

5. Competitive Landscape

  • 5.1. Chapter Overview
  • 5.2. Regional Analysis
  • 5.3. Heat Map Analysis
  • 5.4. Analysis by Source of Cell Lines and Size of Company

6. Company Profiles of Key Players

  • 6.1. Chapter Overview
  • 6.2. Abzena
    • 6.2.1. Company Overview
    • 6.2.2. Financial Performance
    • 6.2.3. Cell Line Development Services and Technology Platforms
    • 6.2.4. Manufacturing Facilities
    • 6.2.5. Recent Developments
      • 6.2.5.1. Collaborations
      • 6.2.5.2. Investments and Expansions
      • 6.2.5.3. Acquisitions
    • 6.2.6. Future Outlook
  • 6.3. Batavia Biosciences
    • 6.3.1. Company Overview
    • 6.3.2. Cell Line Development Services and Technology Platforms
    • 6.3.3. Manufacturing Facilities
    • 6.3.4. Recent Developments
      • 6.3.4.1. Collaborations
      • 6.3.4.2. Investments and Expansions
    • 6.3.5. Future Outlook
  • 6.4. Celonic
    • 6.4.1. Company Overview
    • 6.4.2. Cell Line Development Services and Technology Platforms
    • 6.4.3. Manufacturing Facilities
    • 6.4.4. Recent Developments
      • 6.4.4.1. Collaborations
      • 6.4.4.2. Investments and Expansions
    • 6.4.5. Future Outlook
  • 6.5. CMC Biologics
    • 6.5.1. Company Overview
    • 6.5.2. Cell Line Development Services and Technology Platforms
    • 6.5.3. Manufacturing Facilities
    • 6.5.4. Recent Developments
      • 6.5.4.1. Collaborations
      • 6.5.4.2. Investments and Expansions
      • 6.5.4.3. Acquisitions
    • 6.5.5. Future Outlook
  • 6.6. Cobra Biologics
    • 6.6.1. Company Overview
    • 6.6.2. Financial Performance
    • 6.6.3. Cell Line Development Services and Technology Platforms
    • 6.6.4. Recent Developments
      • 6.6.4.1. Collaborations
      • 6.6.4.2. Investments and Expansions
    • 6.6.5. Future Outlook
  • 6.7. Hyprocell
    • 6.7.1. Company Overview
    • 6.7.2. Cell Line Development Services and Technology Platforms
    • 6.7.3. Future Outlook
  • 6.8. LFB Biomanufacturing
    • 6.8.1. Company Overview
    • 6.8.2. Financial Performance
    • 6.8.3. Cell Line Development Services and Technology Platforms
    • 6.8.4. Manufacturing Facilities
    • 6.8.5. Recent Developments
      • 6.8.5.1. Collaborations
      • 6.8.5.2. Investments and Expansions
    • 6.8.6. Future Outlook
  • 6.9. Lonza
    • 6.9.1. Company Overview
    • 6.9.2. Financial Performance
    • 6.9.3. Cell Line Development Services and Technology Platforms
    • 6.9.4. Manufacturing Facilities
    • 6.9.5. Recent Developments
      • 6.9.5.1. Collaborations
      • 6.9.5.2. Investments and Expansions
      • 6.9.5.3. Acquisitions
      • 6.9.6. Future Outlook
  • 6.10. ProBioGen
    • 6.10.1. Company Overview
    • 6.10.2. Cell Line Development Services and Technology Platforms
    • 6.10.3. Recent Developments
      • 6.10.3.1. Collaborations
      • 6.10.3.2. Investments and Expansions
    • 6.10.4. Future Outlook
  • 6.11. Selexis
    • 6.11.1. Company Overview
    • 6.11.2. Cell Line Development Services and Technology Platforms
    • 6.11.3. Recent Developments
      • 6.11.3.1. Collaborations
      • 6.11.3.2. Investments and Expansions
    • 6.11.4. Future Oulook
  • 6.12. trenzyme
    • 6.12.1. Company Overview
    • 6.12.2. Cell Line Development Services and Technology Platforms
    • 6.12.3. Recent Developments
      • 6.12.3.1. Collaborations
      • 6.12.4. Future Outlook

7. Company Profiles of Additional Players

  • 7.1. Chapter Overview
  • 7.2. Biovian
  • 7.3. Charles River Laboratories
  • 7.4. EuBiologics
  • 7.5. Inno Biologics
  • 7.6. Nanotherapeutics
  • 7.7. Oxford Genetics
  • 7.8. RD-Biotech
  • 7.9. Syngene International
  • 7.10. TPG Biologics
  • 7.11. WuXi Biologics

8. Cell Line Repositories

  • 8.1. Chapter Overview
  • 8.2. American Type Culture Collection (ATCC)
    • 8.2.1. Overview
    • 8.2.2. Services Portfolio
  • 8.3. Leibniz Institute DSMZ
    • 8.3.1. Overview
    • 8.3.2. Services Portfolio
  • 8.4. European Collection of Authenticated Cell Cultures (ECACC)
    • 8.4.1. Overview
    • 8.4.2. Services Portfolio
  • 8.5. Coriell Institute for Medical Research
    • 8.5.1. Overview
      • 8.5.1.1. Services Portfolio

9. Market Forecast

  • 9.1. Chapter Overview
  • 9.2. Forecast Methodology
  • 9.3. Input Data Tables and Assumptions
  • 9.4. Cell Line Development Services Market Outlook, 2017-2027
  • 9.5. Distribution of Future Opportunity by Source of Cell Lines
    • 9.5.1. Cell Line Development Services Market for Mammalian Cells, 2017-2027
    • 9.5.2. Cell Line Development Services Market for Microbial Cells, 2017-2027
    • 9.5.3. Cell Line Development Services Market for Insect Cells, 2017-2027
    • 9.5.4. Cell Line Development Services Market for Other Cells, 2017-2027
  • 9.6. Distribution of Future Opportunity by Geography
    • 9.6.1. Cell Line Development Services Market in North America, 2017-2027
    • 9.6.2. Cell Line Development Services Market in the EU, 2017-2027
    • 9.6.3. Cell Line Development Services Market in Asia, 2017-2027
    • 9.6.4. Cell Line Development Services Market in the Rest of the World, 2017-2027
  • 9.7. Distribution of Future Opportunity by Grade of Cell Lines
    • 9.7.1. Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027
    • 9.7.2. Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027

10. Survey Analysis

  • 10.1. Chapter Overview
    • 10.1.1. Overview of Respondents
    • 10.1.2. Seniority Level of Respondents
  • 10.2. Type of Cell Lines
  • 10.3. Source of Cell Lines
  • 10.4. Applications of Cell Lines
  • 10.5. Cell Line Characterization Services
  • 10.6. Cell Banking Services
  • 10.7. Biologics Manufacturing Services
  • 10.8. Fill / Finish Services

11. Conclusion

  • 11.1. Mammalian and Microbial Cell Lines Continue to be Preferred Over those Derived from Other Sources
  • 11.2. Cell Line Characterization, Cell Banking, Process Development and Other Affiliated Services also form an Important Part of the Services Portfolio of Most of the Players
  • 11.3. Innovative Technologies Developed to Optimize and Scale-up the Overall Cell Line Development Process are Emerging as Key Enablers to Future Growth
  • 11.4. Companies Headquartered in the US and EU Dominate the Market Landscape; Asia is Emerging as an Alternative Destination for Provision of such Services
  • 11.5. The Market Continues to Witness Significant Partnership Activity Indicating a Lucrative Future Potential
  • 11.6. Escalating Biomanufacturing Activities and R&D Initiatives are Expected to Act as Key Drivers of the Market
  • 11.7. Overall, the Cell Line Development Services Market is Poised to Grow at a Steady Pace in the Coming Decade

12. Interview Transcripts

  • 12.1. Chapter Overview
  • 12.2. Fan Chen, Vice President BioProcessing, LakePharma
  • 12.3. Michael Pointek, Managing Director, ARTES Biotechnology
  • 12.4. Nienke Smits, Business Development, ModiQuest
  • 12.5. Oscar Hoogteijling, Business Development Manager, Bioceros

13. Appendix 1: Tabulated Data

14. Appendix 2: List of Companies and Organizations

List of Figures:

  • Figure 3.1: Primary and Secondary Cell Culture
  • Figure 3.2: Recombinant Cell Line Development
  • Figure 3.3: Hybridoma Cell Line Development
  • Figure 3.4: Sources of Non-Mammalian Cell Lines
  • Figure 3.5: Applications of Cell Lines
  • Figure 3.6: Factors Affecting the Utility of Cell Lines
  • Figure 4.1: Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Regions)
  • Figure 4.2: Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Countries)
  • Figure 4.3: Cell Line Development Services Providers: Distribution by Source of Cell Lines
  • Figure 4.4: Cell Line Development Services Providers: Distribution by Type of Cell Lines
  • Figure 4.5: Cell Line Development Services Providers: Distribution by Applications of Cell Lines
  • Figure 4.6: Cell Line Development Services Providers: Distribution by Other Related Services
  • Figure 5.1: Regional Analysis: Distribution by Location of Manufacturing Facility
  • Figure 5.2: Heat Map Analysis: Distribution by Location of Manufacturing Facility and Year of Establishment
  • Figure 5.3: Cell Line Development Services Providers (North America): Distribution by Source of Cell Lines and Size of Company
  • Figure 5.4: Cell Line Development Services Providers (EU): Distribution by Source of Cell Lines and Size of Company
  • Figure 5.5: Cell Line Development Services Providers (Asia): Distribution by Source of Cell Lines and Size of Company
  • Figure 6.1: Abzena: Revenues, FY 2014-FY H1 2017 (EUR Million)
  • Figure 6.2: Abzena: Revenues by Business Divisions, FY 2015-FY 2016 (EUR Million)
  • Figure 6.3: Celonic: CHOvolution Technology
  • Figure 6.4: LFB Group: Revenues, FY 2012-FY 2016 (EUR Million)
  • Figure 6.5: LFB Group: Revenues by Therapeutic Areas and Services, 2016 (EUR Million)
  • Figure 6.6: LFB Biomanufacturing: Cell Line Development Process
  • Figure 6.7: Lonza: Custom Contract Manufacturing Services
  • Figure 6.8: Lonza: Revenues, FY 2012-FY 2016 (CHF Million)
  • Figure 6.9: GS Gene Expression System: Working Principle
  • Figure 6.10: Selexis: Cell Line Development Process
  • Figure 6.11: trenzyme: Cell Line Development Process
  • Figure 8.1: ATCC: Services Portfolio
  • Figure 8.2: Leibniz Institute DSMZ: Biological Material Collection
  • Figure 8.3: ECACC: Biological Material Collection
  • Figure 8.4: ECACC: Services Portfolio
  • Figure 8.5: Coriell Institute of Medical Research: Operating Segments
  • Figure 8.6: Coriell Institute for Medical Research: Services Portfolio
  • Figure 9.1: Cell Line Development Services Market, 2017-2027 (USD Billion)
  • Figure 9.2: Cell Line Development Services Market, 2017 and 2027: Distribution by Source of Cell Lines (USD Million)
  • Figure 9.3: Cell Line Development Services Market for Mammalian Cells, 2017-2027 (USD Billion)
  • Figure 9.4: Cell Line Development Services Market for Microbial Cells, 2017-2027 (USD Million)
  • Figure 9.5: Cell Line Development Services Market for Insect Cells, 2017-2027 (USD Million)
  • Figure 9.6: Cell Line Development Services Market for Other Cells, 2017-2027 (USD Million)
  • Figure 9.7: Cell Line Development Services Market, 2017 and 2027: Distribution by Regions (USD Million)
  • Figure 9.8: Cell Line Development Services Market in North America, 2017-2027 (USD Million)
  • Figure 9.9: Cell Line Development Services Market in the EU, 2017-2027 (USD Million)
  • Figure 9.10: Cell Line Development Services Market in Asia, 2017-2027 (USD Million)
  • Figure 9.11: Cell Line Development Services Market in the Rest of the World, 2017-2027 (USD Million)
  • Figure 9.12: Cell Line Development Services Market, 2017 and 2027: Distribution by Grade of Cell Lines (USD Million)
  • Figure 9.13: Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027 (USD Billion)
  • Figure 9.14: Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027 (USD Million)
  • Figure 10.1: Survey Analysis: Distribution by Location of Organization
  • Figure 10.2: Survey Analysis: Distribution by Location of Manufacturing Facilities
  • Figure 10.3: Survey Analysis: Distribution by Seniority Level of Respondents
  • Figure 10.4: Survey Analysis: Distribution by Types of Cell Lines
  • Figure 10.5: Survey Analysis: Distribution by Source of Cell Lines
  • Figure 10.6: Survey Analysis: Distribution by Applications of Cell Lines
  • Figure 10.7: Survey Analysis: Cell Line Characterization Services
  • Figure 10.8: Survey Analysis: Cell Banking Services
  • Figure 10.9: Survey Analysis: Biologics Manufacturing Services
  • Figure 10.10: Survey Analysis: Fill / Finish Services
  • Figure 11.1: Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Source of Cell Lines
  • Figure 11.2: Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Regions
  • Figure 11.3: Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Grade of Cell Lines

List of Tables:

  • Table 3.1: Comparison of Properties of Finite and Continuous Cell line
  • Table 3.2: Human Cell Lines and Therapeutic Protein Products
  • Table 3.3: Cell Lines and Viral Vaccine Products
  • Table 4.1: Cell Line Development Services Providers: List of Companies
  • Table 4.2: Cell Line Development Services Providers: Distribution by Source of Cell Lines
  • Table 4.3: Cell Line Development Services Providers: Distribution by Type and Application of Cell Lines
  • Table 4.4: Cell Line Development Services Providers: Distribution by Other Related Services
  • Table 6.1: CMC Biologics: Mammalian and Microbial cGMP Manufacturing Capabilities
  • Table 9.1: Input Data and Assumptions: Distribution of Cell Line Development Services Providers by Size of the Company and Grade of Cell Lines
  • Table 9.2: Input Data and Assumptions: Distribution of Price of Cell Lines by Source and Grade of Cell Lines
  • Table 9.3: Input Data and Assumptions: Distribution of Number of Projects Undertaken by Size of Company
  • Table 9.4: Input Data and Assumptions: Distribution of Source of Cell Lines by Percentage of Biopharmaceuticals Produced
  • Table 10.1: Survey Responses: Overview of the Respondents
  • Table 10.2: Survey Responses: Seniority Level of Respondents
  • Table 10.3: Survey Responses: Types of Cell Lines
  • Table 10.4: Survey Responses: Source of Cell Lines
  • Table 10.5: Survey Responses: Applications of Cell Lines
  • Table 10.6: Survey Responses: Cell Line Characterization Services
  • Table 10.7: Survey Responses: Cell Banking Services
  • Table 10.8: Survey Responses: Biologics Manufacturing Services
  • Table 10.9: Survey Responses: Fill / Finish Services
  • Table 13.1: Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Regions)
  • Table 13.2: Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Countries)
  • Table 13.3: Cell Line Development Services Providers: Distribution by Source of Cell Lines
  • Table 13.4: Cell Line Development Services Providers: Distribution by Type of Cell Lines
  • Table 13.5: Cell Line Development Services Providers: Distribution by Applications of Cell Lines
  • Table 13.6: Cell Line Development Services Providers: Distribution by Other Related Services
  • Table 13.7: Abzena: Revenues, FY 2014-FY H1 2017 (EUR Million)
  • Table 13.8: Abzena: Revenues by Business Divisions, FY 2015-2016 (EUR Million)
  • Table 13.9: LFB Group: Revenues, FY 2012-FY 2016 (EUR Million)
  • Table 13.10: LFB Group: Revenues by Therapeutic Areas and Services, 2016 (EUR Million)
  • Table 13.11: Lonza: Revenues, FY 2012-FY 2016 (CHF Million)
  • Table 13.12: Cell Line Development Services Market, 2017-2027: Base Scenario (USD Billion)
  • Table 13.13: Cell Line Development Services Market, 2017-2027: Conservative Scenario (USD Billion)
  • Table 13.14: Cell Line Development Services Market, 2017-2027: Optimistic Scenario (USD Billion)
  • Table 13.15: Cell Line Development Services Market, 2017 and 2027: Distribution by Source of Cell Lines (USD Million)
  • Table 13.16: Cell Line Development Services Market for Mammalian Cells, 2017-2027: Base Scenario (USD Billion)
  • Table 13.17: Cell Line Development Services Market for Mammalian Cells, 2017-2027: Conservative Scenario (USD Billion)
  • Table 13.18: Cell Line Development Services Market for Mammalian Cells, 2017-2027: Optimistic Scenario (USD Billion)
  • Table 13.19: Cell Line Development Services Market for Microbial Cells, 2017-2027: Base Scenario (USD Million)
  • Table 13.20: Cell Line Development Services Market for Microbial Cells, 2017-2027: Conservative Scenario (USD Million)
  • Table 13.21: Cell Line Development Services Market for Microbial Cells, 2017-2027: Optimistic Scenario (USD Million)
  • Table 13.22: Cell Line Development Services Market for Insect Cells, 2017-2027: Base Scenario (USD Million)
  • Table 13.23: Cell Line Development Services Market for Insect Cells, 2017-2027: Conservative Scenario (USD Million)
  • Table 13.24: Cell Line Development Services Market for Insect Cells, 2017-2027: Optimistic Scenario (USD Million)
  • Table 13.25: Cell Line Development Services Market for Other Cells, 2017-2027: Base Scenario (USD Million)
  • Table 13.26: Cell Line Development Services Market for Other Cells, 2017-2027: Conservative Scenario (USD Million)
  • Table 13.27: Cell Line Development Services Market for Other Cells, 2017-2027: Optimistic Scenario (USD Million)
  • Table 13.28: Cell Line Development Services Market, 2017 and 2027: Distribution by Regions (USD Million)
  • Table 13.29: Cell Line Development Services Market in North America, 2017-2027: Base Scenario (USD Million)
  • Table 13.30: Cell Line Development Services Market in North America, 2017-2027: Conservative Scenario (USD Million)
  • Table 13.31: Cell Line Development Services Market in North America, 2017-2027: Optimistic Scenario (USD Million)
  • Table 13.32: Cell Line Development Services Market in the EU, 2017-2027: Base Scenario (USD Million)
  • Table 13.33: Cell Line Development Services Market in the EU, 2017-2027: Conservative Scenario (USD Million)
  • Table 13.34: Cell Line Development Services Market in the EU, 2017-2027: Optimistic Scenario (USD Million)
  • Table 13.35: Cell Line Development Services Market in Asia, 2017-2027: Base Scenario (USD Million)
  • Table 13.36: Cell Line Development Services Market in Asia, 2017-2027: Conservative Scenario (USD Million)
  • Table 13.37: Cell Line Development Services Market in Asia, 2017-2027: Optimistic Scenario (USD Million)
  • Table 13.38: Cell Line Development Services Market in the Rest of the World, 2017-2027: Base Scenario (USD Million)
  • Table 13.39: Cell Line Development Services Market in the Rest of the World, 2017-2027: Conservative Scenario (USD Million)
  • Table 13.40: Cell Line Development Services Market in the Rest of the World, 2017-2027: Optimistic Scenario (USD Million)
  • Table 13.41: Cell Line Development Services Market, 2017 and 2027: Distribution by Grade of Cell Lines (USD Million)
  • Table 13.42: Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Base Scenario (USD Billion)
  • Table 13.43: Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Conservative Scenario (USD Billion)
  • Table 13.44: Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Optimistic Scenario (USD Billion)
  • Table 13.45: Cell Line Development Services Market for Non-GMP Cell Lines, 2017-2027: Base Scenario (USD Million)
  • Table 13.46: Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027: Conservative Scenario (USD Million)
  • Table 13.47: Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027: Optimistic Scenario (USD Million)
  • Table 13.48: Survey Analysis: Distribution by Location of Organization
  • Table 13.49: Survey Analysis: Distribution by Location of Manufacturing Facilities
  • Table 13.50: Survey Analysis: Distribution by Seniority Level of Respondents
  • Table 13.51: Survey Analysis: Distribution by Type of Cell Lines
  • Table 13.52: Survey Analysis: Distribution by Source of Cell Lines
  • Table 13.53: Survey Analysis: Distribution by Applications of Cell Lines
  • Table 13.54: Survey Analysis: Cell Line Characterization Services
  • Table 13.55: Survey Analysis: Cell Banking Services
  • Table 13.56: Survey Analysis: Biologics Manufacturing Services
  • Table 13.57: Survey Analysis: Fill / Finish Services
  • Table 13.58: Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Source of Cell Lines
  • Table 13.59: Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Regions
  • Table 13.60: Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Grade of Cell Lines

Listed Companies:

The following companies and organizations have been mentioned in the report.

  • 1. Abbott Nutrition
  • 2. AbbVie
  • 3. Abcam
  • 4. ABclonal
  • 5. Abeomics
  • 6. Abgenex
  • 7. ABLogiX
  • 8. Abnova
  • 9. Abzena
  • 10. Acambis
  • 11. Accurus Biosciences
  • 12. ACROBiosystems
  • 13. ACYTE Biotech
  • 14. AdAlta
  • 15. ADIENNE Pharma & Biotech
  • 16. Agenus
  • 17. Agilux Laboratories
  • 18. Alexion
  • 19. Algeta
  • 20. Allele Biotechnology and Pharmaceuticals
  • 21. Alligator Bioscience
  • 22. Altogen Labs
  • 23. America Pharma Source
  • 24. American Type Culture Collection (ATCC)
  • 25. Amgen
  • 26. AMPO Biotechnology
  • 27. AMS Biotechnology (AMSBIO)
  • 28. Analytical Biological Services
  • 29. Antitope
  • 30. Applied Biological Materials
  • 31. Aragen Bioscience
  • 32. Areta International
  • 33. arGEN-X
  • 34. Aristi Biotech
  • 35. ARTES Biotechnology
  • 36. Asahi Glass Company (AGC)
  • 37. AscentGene
  • 38. ASLAN Pharmaceuticals
  • 39. ATGCell
  • 40. ATUM
  • 41. AutekBio
  • 42. Avid Bioservices
  • 43. Babraham Research Campus
  • 44. Batavia Biosciences
  • 45. Baxter
  • 46. Baylor Institute for Immunology Research (BIIR)
  • 47. Bex
  • 48. Bhat Bio-Tech
  • 49. Bilthoven Biologicals
  • 50. Bio Farma Indonesia
  • 51. BioAzure Technologies
  • 52. Bioceros (member of Polpharma Biologics)
  • 53. Biocon
  • 54. BioFactura
  • 55. Bioingenium
  • 56. BioInvenu
  • 57. BioLab Innovative Research Technologies (BLIRT)
  • 58. Biomet
  • 59. Bionova Scientific
  • 60. BioPharmaceuticals Australia
  • 61. Biosettia
  • 62. Biotie Therapies
  • 63. Biovian
  • 64. BioWa
  • 65. Blue Stream Laboratories
  • 66. Boehringer Ingelheim BioXcellence
  • 67. Boston Mountain Biotech
  • 68. BPS Bioscience
  • 69. Bristol-Myers Squibb
  • 70. C&M Biolabs
  • 71. California Department of Public Health Food and Drug
  • 72. California Institute for Regenerative Medicine
  • 73. Capital Biosciences
  • 74. Cell Essentials
  • 75. CellaGenics
  • 76. CellBank Australia
  • 77. Cellomics Technology
  • 78. Cellon
  • 79. Celltheon
  • 80. Cellutron
  • 81. Celonic
  • 82. Celplor
  • 83. Celther Polska
  • 84. Cerbios-Pharma
  • 85. Ceva Santé Animale (Ceva)
  • 86. Cevec Pharmaceuticals
  • 87. Charles River Laboratories
  • 88. CLS Cell Lines Service
  • 89. CMC Biologics
  • 90. Cobra Biologics
  • 91. Columbia University
  • 92. Commissariat général à l'égalité des territoires (CGET)
  • 93. Complix
  • 94. Cook Pharmica
  • 95. Coriell Institute for Medical Research
  • 96. Corning
  • 97. CreaCell
  • 98. Creative Biogene
  • 99. Creative Biolabs
  • 100. Creative BioMart
  • 101. Crown Bioscience
  • 102. Crucell (Johnson & Johnson)
  • 103. Curaxys
  • 104. Cytovance Biologics
  • 105. Dainippon Sumito Pharma
  • 106. DC3 Therapeutics
  • 107. Delphi Genetics
  • 108. DiscoverX
  • 109. Dundee Cell Products
  • 110. Eden Biodesign
  • 111. EirGenix
  • 112. Elabscience Biotechnology
  • 113. EMD Serono
  • 114. Emergent BioSolutions
  • 115. EMP Genetech
  • 116. EpiGex
  • 117. Eton Bioscience
  • 118. EuBiologics
  • 119. Eugenom
  • 120. Eurofins Scientific Scientific
  • 121. European Collection of Authenticated Cell Cultures (ECACC)
  • 122. European Equity Partners
  • 123. Euroscreen
  • 124. Evercyte
  • 125. Evotec
  • 126. ExcellGene
  • 127. ExonBIO
  • 128. ExpreS2ion Biotechnologies
  • 129. FairJourney Biologics (FJB)
  • 130. Faron Pharmaceuticals
  • 131. Finnish Bioindustries (FIB)
  • 132. Finnish Fair Foundation
  • 133. FivePrime Therapeutics
  • 134. France Research North & South AIDS-HIV Hepatitis ANRS (National Health Agency for Research on AIDS and Hepatitis)
  • 135. FUJIFILM Diosynth Biotechnologies
  • 136. Fusion Antibodies
  • 137. G&P Biosciences
  • 138. Gala Biotech
  • 139. GamaMabs Pharma
  • 140. GATC Biotech
  • 141. GE Capital
  • 142. GE Equity International Mauritius
  • 143. Gemini Biosciences
  • 144. GeneBeyond
  • 145. GeneCopoeia
  • 146. GENENMED
  • 147. Genlantis
  • 148. GenScript
  • 149. GlaxoSmithKline
  • 150. Goodwin Biotechnology
  • 151. GTP Technology
  • 152. GVK Biosciences (GVK BIO)
  • 153. Harvest Moon Pharmaceuticals
  • 154. HealthTech and Medicines Knowledge Transfer Network
  • 155. Heidelberg Pharma
  • 156. Hera BioLabs
  • 157. Horizon Discovery Group
  • 158. Hyprocell
  • 159. ibidi
  • 160. IBI-Lorenzini
  • 161. ICOS Corporation
  • 162. ImmuNext
  • 163. Immunostep
  • 164. Inno Bio Ventures
  • 165. Inno Biologics
  • 166. Innoprot
  • 167. Innoven Partenaires
  • 168. InSCREENeX
  • 169. Institut national de la santé et de la recherche médicale INSERM (National Institute of Health and Medical Research)
  • 170. Institute of Biotechnology (Research Center Juelich)
  • 171. InVivo BioTech Services (part of BRUKER Daltonics)
  • 172. InvivoGen
  • 173. Irvine Scientific
  • 174. Jenner Institute, Oxford University
  • 175. JHL Biotech
  • 176. JRS Pharma
  • 177. JSR Life Sciences
  • 178. KAHR Medical
  • 179. KBI Biopharma
  • 180. Kodiak Sciences
  • 181. Korea-Seoul Life Science Fund (KSLSF)
  • 182. LakePharma
  • 183. Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen
  • 184. LFB Biomanufacturing
  • 185. LFB Biotechnologies
  • 186. Lonza
  • 187. LPB Group
  • 188. Lubris BioPharma
  • 189. Mabion
  • 190. MabPlex
  • 191. Malaysian National Pharmaceutical Control Bureau (NPCB)
  • 192. MassBiologics
  • 193. MedImmune
  • 194. Merck
  • 195. Merica Technologies
  • 196. Merus
  • 197. MGC Pharmaceuticals
  • 198. Minapharm Pharmaceuticals
  • 199. ModiQuest
  • 200. Monitor Clipper Partners
  • 201. Multispan
  • 202. Nanotherapeutics
  • 203. National Biologics Facility
  • 204. National Human Genome Research Institute
  • 205. National Institute of Aging
  • 206. National Institutes of Health (NIH)
  • 207. New England Biolabs
  • 208. Noble Life Sciences
  • 209. NorClone Biotech Laboratories
  • 210. Novartis
  • 211. Novatein Biosciences
  • 212. Novoprotein
  • 213. Nunc
  • 214. Oak BioSciences
  • 215. Octoplus
  • 216. OncoMed Pharmaceuticals
  • 217. OncoSynergy
  • 218. OneWorld Biotech
  • 219. OSE Immnunotherapeutics
  • 220. Oxford Expression Technologies
  • 221. Oxford Genetics
  • 222. Oxford Immunotec
  • 223. Oxford Leadership
  • 224. PacificGMP
  • 225. Paragon Bioservices
  • 226. PATH
  • 227. Patheon
  • 228. PBM Capital Group
  • 229. Pfizer
  • 230. Pharmaron
  • 231. Pieris Pharmaceuticals
  • 232. Polymun Scientific
  • 233. PolyTherics
  • 234. Precision Antibody
  • 235. Premas Biotech
  • 236. ProBioGen
  • 237. Procter & Gamble
  • 238. Profacgen
  • 239. Progenics Pharmaceuticals
  • 240. Promosome
  • 241. ProNovus Biosciences
  • 242. Protein Sciences
  • 243. Protein Technologies
  • 244. ProteoCell
  • 245. PX'Therapeutics
  • 246. RD-Biotech
  • 247. Recopharma
  • 248. Rentschler Biotechnologie
  • 249. RIKEN BioResource Center
  • 250. Roche
  • 251. Rockland Immunochemicals
  • 252. Rodon Biologics
  • 253. RuiYi
  • 254. SAL Scientific
  • 255. Sanofi Biologics
  • 256. Sanofi Pasteur
  • 257. Sartorius Stedim Biotech (SSB)
  • 258. Sartorius Stedim Cellca
  • 259. SB Drug Discovery
  • 260. SB Protein Expression
  • 261. Selexis
  • 262. Senior Housing Properties Trust
  • 263. Serum Institute of India
  • 264. Shanghai Genomics
  • 265. Shanghai Henlius Biotech
  • 266. Shanghai Medicilon
  • 267. Sheffield University
  • 268. Sigma Aldrich
  • 269. Signosis
  • 270. SinoBiological
  • 271. Slovay Pharmaceuticals
  • 272. Sorrento Therapeutics
  • 273. Speed BioSystems
  • 274. STC Biologics
  • 275. Sundia MediTech
  • 276. Sunomix Biosciences
  • 277. Swedish Orphan Biovitrium
  • 278. Syd Labs
  • 279. Symphogen
  • 280. Syngene International
  • 281. System Biosciences
  • 282. TaiMed Biologics
  • 283. Tanvex BioPharma
  • 284. TCG Lifesciences
  • 285. TeneoBio
  • 286. Terumo
  • 287. Teva Pharmachemie
  • 288. Texcell
  • 289. TG Therapeutics
  • 290. The Antibody Lab
  • 291. The Chemistry Research Soluton (TCRS)
  • 292. The Global Health Investment Fund I (GHIF)
  • 293. The Helmholtz Protein Sample Production Facility (PSPF)
  • 294. Therapure Biopharma
  • 295. Thermo Fisher Scientific
  • 296. Tizona Therapeutics
  • 297. TPG Biologics
  • 298. TransViragen
  • 299. Trend Pharma & Tech
  • 300. Trenzyme
  • 301. Triangle Research Labs (TRL)
  • 302. TwinHelix
  • 303. UCL Institute of Ophthalmology
  • 304. UGA Biopharma
  • 305. United BioLabs
  • 306. University College London (UCL)
  • 307. University of Franche Comté
  • 308. University of Oxford
  • 309. UvA Holding
  • 310. Valneva Austria
  • 311. Vectalys
  • 312. VxP Biologics
  • 313. Warwick Effect Polymers
  • 314. WatsonBio Sciences
  • 315. White Oak Global Advisors
  • 316. WIL Research
  • 317. Wockhardt
  • 318. WuXi AppTec
  • 319. WuXi Biologics
  • 320. WuXi PharmaTec
  • 321. Xencor
  • 322. XOMA Corporation
  • 323. Zymeworks
Back to Top